ARIZ Precision Medicine is a company focused on developing cancer treatments using a combination of biological and nanotechnologies. The company aims to stop cancer at its root cause, preventing cancer growth and metastasis.

ARIZ Precision Medicine

ARIZ Precision Medicine is pre-clinical stage company aiming to selectively target and destroy early-stage drivers of cancer, such as the deregulated PRDM genes and proteins that were previously deemed “undruggable”.  ARIZ set out to prove that cancer cells with PRDM abnormalities could be individually targeted and destroyed without harming normal cells by utilizing knowledge of the PRDM gene family, proprietary siRNA constructs and innovative drug delivery nanotechnologies to target these cancer cells. Proof of principle studies confirmed that this approach selectively killed multiple types of cancer cells (breast, colon, lung, myeloma, etc.) thus ARIZ is continuing in the development of new drug candidates for cancer by pushing these products to testing in animal models of cancer. This will give ARIZ compelling data and intellectual property to share with pharmaceutical companies and, thus, enter into strategic partnerships to take our products to the clinic and then to market. Ultimately, through these efforts, ARIZ intends to cure cancers in a way that preserves a patient’s quality of life and avoids the harmful and adverse effects of current therapies. ARIZ is located in Davis, California and benefits from the combined knowledge of a board of experts in PRDM genes, drug delivery and drug development.

Moneta Ventures

Sacramento Angels

I will be speaking at RNA Leaders USA, taking place on September 4-5, 2024. Join me to accelerate innovation and commercialisation of #RNA therapeutics and vaccines #RNALeaders https://lnkd.in/gXaKFy2C RNA Leaders

ARIZ issued a press release proudly announcing the granting of our foundational patent by the USPTO for our siRNA-based therapeutic for lung and other cancers. Many thanks to Maya Skubatch and the team at Wilson Sonsini Goodrich & Rosati

https://lnkd.in/gA8srKQn

Proud to announce that ARIZ Precision Medicine has been selected as a Backyards Award finalist in the "Breakthrough Innovation" category.  Winners will be announced during the GFX2023 conference on October 5th.  Thanks so much to Growth Factory and Stoel Rives LLP!  Join us on the 5th to hear about our progress in developing a precision-based therapeutic for lung cancer.

Metric
Company Name	ARIZ Precision Medicine
Symbol
MSH ID	COM:ARIZBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	3
Website	arizbio.com
LinkedIn	arizbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ARIZ

COM:ARIZBIO

ARIZ Precision Medicine

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue